1,2-dipalmitoyl-3-phosphatidylethanolamine has been researched along with Adenocarcinoma in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arpicco, S; Cattel, L; Costanzo, C; Dalla Pozza, E; Dando, I; Donadelli, M; Fattal, E; Lerda, C; Palmieri, M; Stella, B; Tsapis, N | 1 |
| Arpicco, S; Beghelli, S; Costanzo, C; Dalla Pozza, E; Dando, I; Donadelli, M; Fattal, E; Lerda, C; Palmieri, M; Scarpa, A; Scupoli, MT; Zoratti, E | 1 |
| Brandes, LJ; Klapp, K; Lieskovsky, G; Quinn, DI; Raghavan, D; Ramsey, EW; Snyder, T; Styles, E; Tsao-Wei, D | 1 |
1 trial(s) available for 1,2-dipalmitoyl-3-phosphatidylethanolamine and Adenocarcinoma
| Article | Year |
|---|---|
Phase II trial of tesmilifene plus mitoxantrone and prednisone for hormone refractory prostate cancer: high subjective and objective response in patients with symptomatic metastases.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Male; Maximum Tolerated Dose; Middle Aged; Mitoxantrone; Neoplasm Staging; Phosphatidylethanolamines; Prednisone; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Survival Analysis; Treatment Outcome | 2005 |
2 other study(ies) available for 1,2-dipalmitoyl-3-phosphatidylethanolamine and Adenocarcinoma
| Article | Year |
|---|---|
Hyaluronic acid-coated liposomes for active targeting of gemcitabine.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Cell Line, Tumor; Deoxycytidine; Drug Delivery Systems; Gene Expression Regulation, Neoplastic; Humans; Hyaluronan Receptors; Hyaluronic Acid; Liposomes; Molecular Weight; Pancreatic Neoplasms; Phosphatidylethanolamines; Prodrugs | 2013 |
Targeting gemcitabine containing liposomes to CD44 expressing pancreatic adenocarcinoma cells causes an increase in the antitumoral activity.
Topics: 1,2-Dipalmitoylphosphatidylcholine; Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Cells, Cultured; Cholesterol; Deoxycytidine; Flow Cytometry; Gemcitabine; Humans; Hyaluronan Receptors; Hyaluronic Acid; Liposomes; Mice; Mice, Nude; Microscopy, Confocal; Pancreatic Neoplasms; Phosphatidylethanolamines; Prodrugs; Tumor Burden; Xenograft Model Antitumor Assays | 2013 |